Klaus B. Rohr

Ingelheim Am Rhein, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.

Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.

Journal: ERJ open research

Published: February 03, 2025

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.

Journal: ERJ open research

Published: June 19, 2024

Acute exacerbations in patients with progressive pulmonary fibrosis.

Acute exacerbations in patients with progressive pulmonary fibrosis.

Journal: ERJ open research

Published: April 18, 2024

The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.

The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.

Journal: Respiratory investigation

Published: February 02, 2024

Worsening dyspnoea as a predictor of progression of pulmonary fibrosis.

Worsening dyspnoea as a predictor of progression of pulmonary fibrosis.

Journal: The European respiratory journal

Published: December 10, 2023

Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.

Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis.

Journal: The European respiratory journal

Published: May 04, 2023

Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.

Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.

Journal: Respirology (Carlton, Vic.)

Published: June 29, 2022

Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.

Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.

Journal: Respiratory investigation

Published: March 04, 2022

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.

Journal: Advances in therapy

Published: February 08, 2022

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.

Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.

Journal: BMJ open respiratory research

Published: December 08, 2021

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.

Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.

Journal: ERJ open research

Published: December 02, 2021

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.

Journal: Advances in therapy

Published: October 15, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026